Prophylaxis of migraine: General principles and patient acceptance

Neuropsychiatric Disease and Treatment

Volumn 4, Issue 6, 2008, Pages 1155-1167

  D'Amico, Domenico ^a   Tepper, Stewart J ^b  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acceptance; Adherence; Migraine; Preventive therapy; Prophylaxis

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ATENOLOL; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYPROHEPTADINE; DOXEPIN; ERGOT ALKALOID; FLUNARIZINE; GABAPENTIN; IMIPRAMINE; MAGNESIUM; METHYSERGIDE; METOPROLOL; NADOLOL; NORTRIPTYLINE; PIZOTIFEN; PROPRANOLOL; PROTRIPTYLINE; RIBOFLAVIN; SEROTONIN 2 ANTAGONIST; TIMOLOL; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNINDEXED DRUG; VALPROIC ACID; VERAPAMIL;

ALOPECIA; ANHIDROSIS; ASTHENIA; ATRIOVENTRICULAR BLOCK; BLURRED VISION; BRADYCARDIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONCENTRATION LOSS; CONSTIPATION; DIARRHEA; DIET SUPPLEMENTATION; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSPEPSIA; FATIGUE; GASTROINTESTINAL DISEASE; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HUMAN; HYPERCHLOREMIC ACIDOSIS; INAPPROPRIATE VASOPRESSIN SECRETION; LANGUAGE DISABILITY; LEG PAIN; LIFESTYLE MODIFICATION; LIVER TOXICITY; LONG TERM CARE; MANIA; MEMORY DISORDER; MIGRAINE; MONOTHERAPY; NAUSEA; NEPHROLITHIASIS; NEURAL TUBE DEFECT; NEUROPATHOLOGY; NONHUMAN; OPTIMAL DRUG DOSE; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PAIN; PARESTHESIA; PATIENT EDUCATION; PATIENT PARTICIPATION; POPULATION RESEARCH; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SEDATION; SIDE EFFECT; TACHYCARDIA; TERATOGENICITY; TREATMENT DURATION; TREATMENT REFUSAL; TREATMENT RESPONSE; TREMOR; URINE COLOR; URINE RETENTION; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 60249098271     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/ndt.s3497     Document Type: Review

References (78)

1. Ayata C, Jin H, Kudo C, et al. 2006. Suppression of cortical spreading depression in migraine prophylaxis. Ann Neurol, 59:652-61.
2. Bigal ME, Rapoport AM, Lipton RB, et al. 2003. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache, 43:336-42.
3. Bigal ME, Lipton RB. 2006. Modifiable risk factors for migraine progression (or for chronic daily headaches) - clinical lessons. Headache, 46 (Suppl 3):S14445.
4. Blau JN. 1980. Migraine prodromes separated from the aura: Complete migraine. BMJ, 281:658-60.
5. Blau JN. 1984. Resolution of migraine attacks: Sleep and the recovery phase. J Neurol Neurosurg Psychiatry, 47:437-42.
6. Brandes JL, Saper JR, Diamond M, et al; for the MIGR-002 Study Group. 2004. Topiramate for migraine prevention: a randomized controlled trial. JAMA, 291(8):965-73.
7. Brandes JL, Kudrow DB, Rothrock JF, et al. 2006. Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clin Proc, 81(10):1311-9.
8. Dahlof CGH, Dimenas E. 1995. Migraine patients experience poorer subjective well-being/quality of life even between attacks. Cephalalgia, 15:31-6.
9. Dahlof C, Loder E, Diamond M, et al. 2007. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes, 4;5(1):56.
10. D'Amico D, Usai S, Grazzi L, et al. 2003. Quality of life and disability in primary chronic daily headaches. Neurol Sci, 24:S97-S100.
11. D'Amico D, Usai S, Grazzi L, et al. 2004. The impact of primary headaches on patients' lives: Italian experience with the MIDAS and the SF-36 questionnaires. Headache Care, 1:123-8.
12. D'Amico D, Grazzi L, Usai S, et al. 2005. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache, 45:553-60.
13. D'Amico D, Lanteri-Minet M. 2006. Migraine preventive therapy: selection of appropriate patients and general principles of management. Expert Rev Neurother, 6:1147-57.
14. D'Amico D, Leone M, Grazzi L, et al. 2008. When should "chronic migraine" patients be considered "refractory" to pharmacological prophylaxis? Neurol Sci, 29(Suppl 1):S55-58.
15. Davies GM, Santanello N, Lipton RB. 2000. Determinants of patient satisfaction with migraine therapy. Cephalalgia, 20:554-60.
16. Diamond ML, Wenzel RG, Nissan GR. 2006. Optimizing migraine therapy: evidence-based and patient-centered care. Expert Rev Neurother, 6:911-9.
17. Diez FI, Straube A, Zanchin G. 2007. Patient preference in migraine therapy. A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol, 254:242-9.
18. Dowson AJ, Sender J, Lipscombe S, et al. 2003. Establishing principles for migraine management in primary care. Int J Clin Pract, 57:493-507.
19. Dowson AJ, Tepper SJ, Baos V, et al. 2004. Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire. Current Med Res Opin, 20:1125-35.
20. Dowson AJ, Tepper SJ, Dahlof C. 2005. Patients' preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine. J Headache Pain, 6:112-20.
21. Diamond S, Bigal ME, Silberstein S, et al. 2007. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention Study. Headache, 47:355-63.
22. D'Amico D, Solari A, Usai S, et al; for the Progetto Cefalee Lombardia Group. 2006. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudinal multicentre study. Cephalalgia, 26:691-96.
23. Diener HC, Tfelt Hansen P, Dahlof C, et al; for the MIGR-003 Study Group. 2004. Topiramate in migraine prophylaxis - results from a placebo-controlled trial with propranolol as an active control. J Neuro, 251:943-50.
24. Diener HC, Agosti R, Allais G, et al; for the TOPMAT-MIG-303 Investigators Group. 2007. Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial. Lancet Neurol, 6:1054-62.
25. Dueland AN, Leira R, Burke TA, et al. 2004. The impact of migraine on work, family, and leisure among young women - a multinational study. Curr Med Res Opin, 20:1595-604.
26. Goadsby PJ, Dodick DW, Ferrari MD, et al. 2004. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management. Acta Neuro. Scand, 110:137-43.
27. Guitera V, Munoz P, Castillo J, et al. 2002. Quality of life in chronic daily headache: a study in a general population. Neurology, 58:1062-5.
28. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, et al. 2004. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest, 113:1447-55.
29. Headache Classification Subcommittee of the International Headache Society. 2004. The international classification of headache disorders: 2nd edition. Cephalalgia, 24(Suppl 1):1-160.
30. Henry P, Auray JP, Gaudin AF et al. 2002. Prevalence and clinical characteristics of migraine in France. Neurology, 59:232-7.
31. Joffe H, Cohen LS, Suppes T, et al. 2006. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Biol Psychiatry, 59:1078-86.
32. Katsarava Z, Schneeweiss S, Kurth T, et al. 2004. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology, 62:788-90.
33. Klapper J. 1997. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia, 17:103-38.
34. Kol CM, Dekker F, Neven AK, et al. 2008. Acceptance or rejection of prophylactic medicine in patients with migraine: a cross-sectional study. Br J Gen Pract, 58:98-101.
35. Kosinski M, Bayliss MS, Bjorner JB, et al. 2003. A six-item short-form survey for measuring headache impact: the HIT-6. Qual Life Res, 12:963-74.
36. Lainez M J, Evers S, Kinge E, et al. 2006. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia, 26:246-56.
37. Launer LJ, Terwindt GM, Ferrari MD. 1999. The prevalence and characteristics of migraine in a population-based cohort. Neurology, 53:537-42.
38. Lipton RB, Stewart WF, Diamond S, et al. 2001. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache, 41:646-57.
39. Lipton RB, Bigal ME, Kolodner K, et al. 2003. The family impact of migraine: population-based studies in the USA and UK. Cephalalgia, 23:429-40.
40. Lipton RB, Sher AI, Steiner TJ, et al. 2003. Patterns of health care utilization for migraine in England and in the United States. Neurology, 60:441-8.
41. Lipton RB, Göbel H, Einhäupl KM, et al. 2004. Petasites hybridus root (butterbur) is an effective preventive treatment for migraine. Neurology, 63:2240-4.
42. Lipton RB, Bigal ME, Diamond M, et al. 2007. AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology, 68:343-9.
43. Lucas C, Chaffaut C, Artaz MA, et al. 2005. FRAMIG 2000: medical and therapeutic management of migraine in France. Cephalalgia, 25:267-79.
44. Lucas C, Géraud G, Valade D, et al. 2006. Recognition and therapeutic management of migraine in 2004, in France: results of FRAMIG 3, a French nationwide population-based survey. Headache, 46:715-25.
45. MacGregor E A, Brandes J, Eikermann A. 2003. Migraine Prevalence and Treatment Patterns: The Global Migraine and Zolmitriptan Evaluation Survey. Headache, 43:19-26.
46. Manzoni CG, Yorelli P. 2007. The patient - physician relationship in the approach to therapeutic management. Neurol Sci, 28:S130-S133.
47. Mathew NT, Stubits E, Nigam MR. 1982. Transformation of migraine into daily headache: analysis of factors. Headache, 22:66-8.
48. Mathew NT, Rapoport A, Saper J, et al. 2001. Efficacy of gabapentin in migraine prophylaxis. Headache, 41:119-28.
49. Meletiche DM, Lofland JH, Young WB. 2001. Quality-of life differences between patients with episodic and transformed migraine. Headache, 41:573-8.
50. Members of the task force: Evers S, Afra J, Frese A, et al. 2006. EFNS guideline on the drug treatment of migraine - report of an EFNS task force. Eur J Neurol, 13:560-72.
51. Monzón MJ, Láinez MJ. 1998. Quality of life in migraine and chronic daily headache patients. Cephalalgia, 18:638-43.
52. Osterhaus JT, Townsend RJ, Gandek B, et al. 1994. Measuring the functional status and well-being of patients with migraine headache. Headache, 34:337-43.
53. Peres MF, Silberstein S, Moreira F, et al. 2007. Patients' preference for migraine preventive therapy. Headache, 47:540-5.
54. Powers C, Szeto S, Pangtay D, et al. 2000. Evaluation of migraineurs' preferences for naratriptan over conventional first-line agents. Arch Faro Med, 9:753-8.
55. Ramadan NM, Silberstein SD, Freitag FG, et al. 2000. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Neurology, (serial on line) www.neurology.org.
56. Rapoport A, Mauskop A, Diener HC, et al. 2006. Long-term migraine prevention with topiramate: open-label extension of pivotal trials. Headache, 46:1151-60.
57. Roncolato M, Fabbri L, Recchia G, et al. 2000. An epidemiological study to assess migraine prevalence in a sample of Italian population presenting to their GPs. Eur Neurol, 43:102-6.
58. Roth BL. 2007. Drugs and valvular heart disease. N Engl J Med, 356:6-9.
59. Rozen TD. 2006. Migraine prevention: what patients want from medication and their physicians (a headache specialty clinic perspective). Headache, 46:750-3.
60. Salonen R, Ashford EA, Gibbs M, et al. 1999. Patient preference for oral sumatriptan 25 mg, 50 mg, or 100 mg in the acute treatment of migraine: a double-blind, randomized, crossover study. Sumatriptan Tablets S2CM11 Study Group. Int J Clin Pract, (Suppl) 105:16-22.
61. Sándor PS, Afra J, Ambmsini A, et al. 2000. Prophylactic treatment of migraine with beta-blockers and riboflavin: differential effects on the intensity dependence of auditory evoked cortical potentials. Headache, 40:30-5.
62. Scher AI, Stewart WF, Ricci JA, et al. 2003. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain, 106:81-9.
63. Sheftell FD, Feleppa M, Tepper SJ, et al. 2004. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population. Headache, 44:661-8.
64. Silberstein SD, Silberstein MM. 1990. New concepts in the pathognesis of headache-Part II. Pain Manag, 3:334-42.
65. Silberstein SD, Lipton RB, Sliwinski M. 1996. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology, 47:871-5.
66. Silberstein SD; for the US Headache Consortium. 2000. Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standars Subcommittee of the American Academy of Neurology. Neurology, 55:754-62.
67. Silberstein SD, Goadsby PJ. 2002. Migraine: preventive treatment. Cephalalgia, 22:491-512.
68. Silberstein SD, Neto W, Schmitt J, et al; and the MIGR-001 Study Group. 2004. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol, 61:490-5.
69. Silberstein SD, Dodick D, Freitag F, et al. 2007. Pharmacological approaches to managing migraine and associated comorbidities - clinical considerations for monotherapy versus polytherapy. Headache, 47:585-99.
70. Steiner TJ, Scher AI, Stewart WF, et al. 2003. The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity. Cephalalgia, 23:519-27.
71. Stewart WF, Sheder AL, Simon D, et al. 1994. Migraine prevalence. A review of population-based studies. Neurology, 44(Suppl 4):S17-S23.
72. Stewart WF, Shechter A, Lipton RB. 1994. Migraine heterogeneity. Disability, pain intensity, and attack frequency and duration. Neurology, 44(6 Suppl 4):S24-33.
73. Stewart WF, Lipton RB, Whyte J, et al. 1999. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology, 53:988-94.
74. Tepper SJ, D'Amico D, Bans V, et al. 2004. Guidelines for prescribing prophylactic medications for migraine: a survey among headache specialists in different countries. Headache Care, 1:267-72.
75. Tepper SJ, Bigal, M, Rapoport A, Sheftell F. Alternative therapies: evidence based evaluation in migraine. Headache Care, 2006, 3:57-64.
76. Terwindt GM, Ferrari MD, Tijhuis M, et al. 2000. The impact of migraine on quality of life in the general population. Neurology, 55:624-9.
77. Wang SJ. 2003. Epidemiology of migraine and other types of headache in Asia. Curr Neurol Neurosci Rep, 3:104-8.
78. Ziad el K, Rahi AC, Hamdan SA, et al. 2005. Age, dose, and environmental temperature are risk factors for topiramate-related hyperthermia. Neurology, 65:1139-40.